{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:48:27Z","timestamp":1785163707528,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R33CA235319"],"award-info":[{"award-number":["R33CA235319"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R42CA183376"],"award-info":[{"award-number":["R42CA183376"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["P3006360"],"award-info":[{"award-number":["P3006360"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Noninvasive detection of early-stage liver metastases from different primary cancers is a pressing unmet medical need. The lack of both molecular biomarkers and the sensitive imaging methodology makes the detection challenging. In this study, we observed the elevated expression of chemokine receptor 4 (CXCR4) in uveal melanoma (UM) patient liver tissues, and high CXCR4 expression in liver metastases of UM murine models, regardless of the expression levels in the primary tumors. Based on these findings, we identified CXCR4 as an imaging biomarker and exploited a CXCR4-targeted MRI contrast agent ProCA32.CXCR4 for molecular MRI imaging. ProCA32.CXCR4 has strong CXCR4 binding affinity, high metal selectivity, and r1 and r2 relaxivities, which enables the sensitive detection of liver micrometastases. The MRI imaging capacity for detecting liver metastases was demonstrated in three UM models and one ovarian cancer model. The imaging results were validated by histological and immunohistochemical analysis. ProCA32.CXCR4 has strong potential clinical application for non-invasive diagnosis of liver metastases.<\/jats:p>","DOI":"10.1038\/s41417-022-00433-w","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T09:02:55Z","timestamp":1644483775000},"page":"1827-1839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Non-invasive detection and complementary diagnosis of liver metastases via chemokine receptor 4 imaging"],"prefix":"10.1038","volume":"29","author":[{"given":"Hua","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4303-3916","authenticated-orcid":false,"given":"Shanshan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-6531","authenticated-orcid":false,"given":"Jingjuan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongxiang","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6734-8779","authenticated-orcid":false,"given":"Yuguang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangda","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatosin Y.","family":"Ibhagui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-9712","authenticated-orcid":false,"given":"Hans E.","family":"Grossniklaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2310-7658","authenticated-orcid":false,"given":"Jenny J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"433_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559\u201364.","journal-title":"Science"},{"key":"433_CR2","doi-asserted-by":"publisher","first-page":"570","DOI":"10.18632\/oncotarget.2677","volume":"6","author":"J Budczies","year":"2015","unstructured":"Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz JK, Denkert C, et al. The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015;6:570\u201383.","journal-title":"Oncotarget"},{"key":"433_CR3","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1002\/cam4.1697","volume":"7","author":"M Riihimaki","year":"2018","unstructured":"Riihimaki M, Thomsen H, Sundquist K, Sundquist J, Hemminki K. Clinical landscape of cancer metastases. Cancer Med. 2018;7:5534\u201342.","journal-title":"Cancer Med"},{"key":"433_CR4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/archopht.119.5.670","volume":"119","author":"Collaborative Ocular Melanoma Study G.","year":"2001","unstructured":"Collaborative Ocular Melanoma Study G. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119:670\u20136.","journal-title":"Arch Ophthalmol"},{"key":"433_CR5","first-page":"377","volume":"57","author":"A Furdova","year":"2010","unstructured":"Furdova A, Slezak P, Chorvath M, Waczulikova I, Sramka M, Kralik G. No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma. Neoplasma. 2010;57:377\u201381.","journal-title":"Neoplasma"},{"key":"433_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4137\/CGM.S31244","volume":"8","author":"S Friberg","year":"2015","unstructured":"Friberg S, Nystrom A. Cancer metastases: early dissemination and late recurrences. Cancer Growth Metastasis. 2015;8:43\u20139.","journal-title":"Cancer Growth Metastasis"},{"key":"433_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5005\/jp-journals-10018-1241","volume":"7","author":"AI Valderrama-Trevino","year":"2017","unstructured":"Valderrama-Trevino AI, Barrera-Mera B, Ceballos-Villalva JC, Montalvo-Jave EE. Hepatic metastasis from colorectal cancer. Euroasian J Hepatogastroenterol. 2017;7:166\u201375.","journal-title":"Euroasian J Hepatogastroenterol"},{"key":"433_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000184739","volume":"25","author":"CW Michalski","year":"2008","unstructured":"Michalski CW, Erkan M, Huser N, Muller MW, Hartel M, Friess H, et al. Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg. 2008;25:473\u201380.","journal-title":"Dig Surg"},{"key":"433_CR9","first-page":"6919","volume":"35","author":"N Bacalbasa","year":"2015","unstructured":"Bacalbasa N, Balescu I, Dima S, Popescu I. Long-term survivors after liver resection for ovarian cancer liver metastases. Anticancer Res. 2015;35:6919\u201323.","journal-title":"Anticancer Res"},{"key":"433_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern M-H, et al. Uveal melanoma. Nat Rev Dis Prim. 2020;6:24.","journal-title":"Nat Rev Dis Prim"},{"key":"433_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/lt.500050113","volume":"5","author":"MA Choti","year":"1999","unstructured":"Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transpl Surg. 1999;5:65\u201380.","journal-title":"Liver Transpl Surg"},{"key":"433_CR12","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00259-008-0743-z","volume":"35","author":"G Kong","year":"2008","unstructured":"Kong G, Jackson C, Koh DM, Lewington V, Sharma B, Brown G, et al. The use of 18F-FDG PET\/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging. 2008;35:1323\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"433_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jhep.2005.07.015","volume":"43","author":"R Stigliano","year":"2005","unstructured":"Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for HCC before liver transplantation? -no, please don\u2019t. J Hepatol. 2005;43:563\u20138.","journal-title":"J Hepatol"},{"key":"433_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1148\/radiol.11110157","volume":"261","author":"DJ Becker-Weidman","year":"2011","unstructured":"Becker-Weidman DJ, Kalb B, Sharma P, Kitajima HD, Lurie CR, Chen Z, et al. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging-comparison to prior same-center results after MR systems improvements. Radiology. 2011;261:824\u201333.","journal-title":"Radiology"},{"key":"433_CR15","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1167\/iovs.14-14550","volume":"55","author":"KG Ewens","year":"2014","unstructured":"Ewens KG, Kanetsky PA, Richards-Yutz J, Purrazzella J, Shields CL, Ganguly T, et al. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Investigative Ophthalmol Vis Sci. 2014;55:5160\u20137.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"433_CR16","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ophtha.2012.02.017","volume":"119","author":"MD Onken","year":"2012","unstructured":"Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:1596\u2013603.","journal-title":"Ophthalmology"},{"key":"433_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","volume":"124","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31\u201382.","journal-title":"Adv Cancer Res"},{"key":"433_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ophtha.2017.07.018","volume":"125","author":"E Szalai","year":"2018","unstructured":"Szalai E, Wells JR, Ward L, Grossniklaus HE. Uveal melanoma nuclear BRCA1-associated protein-1 immunoreactivity is an indicator of metastasis. Ophthalmology. 2018;125:203\u20139.","journal-title":"Ophthalmology"},{"key":"433_CR19","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410\u20133.","journal-title":"Science"},{"key":"433_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/1535-7163.MCT-17-0643","volume":"17","author":"A Figueras","year":"2018","unstructured":"Figueras A, Alsina-Sanchis E, Lahiguera A, Abreu M, Muinelo-Romay L, Moreno-Bueno G, et al. A role for CXCR4 in peritoneal and hematogenous ovarian cancer dissemination. Mol Cancer Ther. 2018;17:532\u201343.","journal-title":"Mol Cancer Ther"},{"key":"433_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1167\/iovs.07-1035","volume":"49","author":"H Li","year":"2008","unstructured":"Li H, Alizadeh H, Niederkorn JY. Differential expression of chemokine receptors on uveal melanoma cells and their metastases. Investig Ophthalmol Vis Sci. 2008;49:636\u201343.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"433_CR22","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1158\/1078-0432.CCR-18-1368","volume":"25","author":"L Dong","year":"2019","unstructured":"Dong L, You S, Zhang Q, Osuka S, Devi NS, Kaluz S, et al. Arylsulfonamide 64B inhibits hypoxia\/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma. Clin Cancer Res. 2019;25:2206\u201318.","journal-title":"Clin Cancer Res"},{"key":"433_CR23","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1111\/j.1755-3768.2012.02515.x","volume":"90","author":"BC Dobner","year":"2012","unstructured":"Dobner BC, Riechardt AI, Joussen AM, Englert S, Bechrakis NE. Expression of haematogenous and lymphogenous chemokine receptors and their ligands on uveal melanoma in association with liver metastasis. Acta Ophthalmol. 2012;90:e638\u201344.","journal-title":"Acta Ophthalmol"},{"key":"433_CR24","first-page":"T5","volume":"114","author":"MJ Jager","year":"2016","unstructured":"Jager MJ, Magner JA, Ksander BR, Dubovy SR. Uveal melanoma cell lines: where do they come from? (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2016;114:T5.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"433_CR25","first-page":"607","volume":"17","author":"BL Burgess","year":"2011","unstructured":"Burgess BL, Rao NP, Eskin A, Nelson SF, McCannel TA. Characterization of three cell lines derived from fine needle biopsy of choroidal melanoma with metastatic outcome. Mol Vis. 2011;17:607\u201315.","journal-title":"Mol Vis"},{"key":"433_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1755-148X.2012.00971.x","volume":"25","author":"KG Griewank","year":"2012","unstructured":"Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, et al. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res. 2012;25:182\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"key":"433_CR27","doi-asserted-by":"publisher","first-page":"119478","DOI":"10.1016\/j.biomaterials.2019.119478","volume":"224","author":"M Salarian","year":"2019","unstructured":"Salarian M, Yang H, Turaga RC, Tan S, Qiao J, Xue S, et al. Precision detection of liver metastasis by collagen-targeted protein MRI contrast agent. Biomaterials. 2019;224:119478.","journal-title":"Biomaterials"},{"key":"433_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11984-2","volume":"10","author":"M Salarian","year":"2019","unstructured":"Salarian M, Turaga RC, Xue S, Nezafati M, Hekmatyar K, Qiao J, et al. Early detection and staging of chronic liver diseases with a protein MRI contrast agent. Nat Commun. 2019;10:4777.","journal-title":"Nat Commun"},{"key":"433_CR29","doi-asserted-by":"publisher","first-page":"12668","DOI":"10.1039\/C5NR09071G","volume":"8","author":"F Pu","year":"2016","unstructured":"Pu F, Salarian M, Xue S, Qiao J, Feng J, Tan S, et al. Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI. Nanoscale. 2016;8:12668\u201382.","journal-title":"Nanoscale"},{"key":"433_CR30","doi-asserted-by":"publisher","first-page":"6607","DOI":"10.1073\/pnas.1423021112","volume":"112","author":"S Xue","year":"2015","unstructured":"Xue S, Yang H, Qiao J, Pu F, Jiang J, Hubbard K, et al. Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. Proc Natl Acad Sci USA. 2015;112:6607\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"433_CR31","doi-asserted-by":"publisher","first-page":"eaav7504","DOI":"10.1126\/sciadv.aav7504","volume":"6","author":"S Tan","year":"2020","unstructured":"Tan S, Yang H, Xue S, Qiao J, Salarian M, Hekmatyar K, et al. Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases. Sci Adv. 2020;6:eaav7504.","journal-title":"Sci Adv"},{"key":"433_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ygyno.2006.02.036","volume":"103","author":"YP Jiang","year":"2006","unstructured":"Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol. 2006;103:226\u201333.","journal-title":"Gynecol Oncol"},{"key":"433_CR33","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1593\/neo.111076","volume":"13","author":"P Ray","year":"2011","unstructured":"Ray P, Lewin SA, Mihalko LA, Schmidt BT, Luker KE, Luker GD. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. Neoplasia. 2011;13:1152\u201361.","journal-title":"Neoplasia"},{"key":"433_CR34","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1158\/1078-0432.CCR-06-2630","volume":"14","author":"S Bakalian","year":"2008","unstructured":"Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res. 2008;14:951\u20136.","journal-title":"Clin Cancer Res"},{"key":"433_CR35","first-page":"101042831770620","volume":"39","author":"YP Li","year":"2017","unstructured":"Li YP, Pang J, Gao S, Bai PY, Wang WD, Kong P, et al. Role of CXCR4 and SDF1 as prognostic factors for survival and the association with clinicopathology in colorectal cancer: a systematic meta-analysis. Tumour Biol: J Int Soc Oncodev Biol Med. 2017;39:1010428317706206.","journal-title":"Tumour Biol: J Int Soc Oncodev Biol Med"},{"key":"433_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5483\/BMBRep.2014.47.1.069","volume":"47","author":"J Li","year":"2014","unstructured":"Li J, Jiang K, Qiu X, Li M, Hao Q, Wei L, et al. Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer. BMB Rep. 2014;47:33\u20138.","journal-title":"BMB Rep"},{"key":"433_CR37","first-page":"1159","volume":"16","author":"T Wehler","year":"2006","unstructured":"Wehler T, Wolfert F, Schimanski CC, Gockel I, Herr W, Biesterfeld S, et al. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol Rep. 2006;16:1159\u201364.","journal-title":"Oncol Rep"},{"key":"433_CR38","doi-asserted-by":"publisher","first-page":"e34038","DOI":"10.1371\/journal.pone.0034038","volume":"7","author":"Z Liang","year":"2012","unstructured":"Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, et al. Development of a unique small molecule modulator of CXCR4. PLoS ONE. 2012;7:e34038.","journal-title":"PLoS ONE"},{"key":"433_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1167\/iovs.12-10643","volume":"54","author":"H Li","year":"2013","unstructured":"Li H, Niederkorn JY, Sadegh L, Mellon J, Chen PW. Epigenetic regulation of CXCR4 expression by the ocular microenvironment. Investigative Ophthalmol Vis Sci. 2013;54:234\u201343.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"433_CR40","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jamaophthalmol.2013.2547","volume":"131","author":"HE Grossniklaus","year":"2013","unstructured":"Grossniklaus HE. Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. JAMA Ophthalmol. 2013;131:462\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"433_CR41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/02713680600718962","volume":"31","author":"H Yang","year":"2006","unstructured":"Yang H, Grossniklaus HE. Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res. 2006;31:557\u201362.","journal-title":"Curr Eye Res"},{"key":"433_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5712-3","volume":"19","author":"NM Jones","year":"2019","unstructured":"Jones NM, Yang H, Zhang Q, Morales-Tirado VM, Grossniklaus HE. Natural killer cells and pigment epithelial-derived factor control the infiltrative and nodular growth of hepatic metastases in an Orthotopic murine model of ocular melanoma. BMC Cancer. 2019;19:484.","journal-title":"BMC Cancer"},{"key":"433_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000370153","volume":"1","author":"H Yang","year":"2015","unstructured":"Yang H, Cao J, Grossniklaus HE. Uveal melanoma metastasis models. Ocul Oncol Pathol. 2015;1:151\u201360.","journal-title":"Ocul Oncol Pathol"},{"key":"433_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ophtha.2017.09.029","volume":"125","author":"A Liao","year":"2018","unstructured":"Liao A, Mittal P, Lawson DH, Yang JJ, Szalai E, Grossniklaus HE. Radiologic and histopathologic correlation of different growth patterns of metastatic uveal melanoma to the liver. Ophthalmology. 2018;125:597\u2013605.","journal-title":"Ophthalmology"},{"key":"433_CR45","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.mri.2007.11.002","volume":"26","author":"K Hanaoka","year":"2008","unstructured":"Hanaoka K, Lubag AJ, Castillo-Muzquiz A, Kodadek T, Sherry AD. The detection limit of a Gd3+-based T1 agent is substantially reduced when targeted to a protein microdomain. Magn Reson Imaging. 2008;26:608\u201317.","journal-title":"Magn Reson Imaging"},{"key":"433_CR46","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrd1134","volume":"2","author":"E De Clercq","year":"2003","unstructured":"De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Disco. 2003;2:581\u20137.","journal-title":"Nat Rev Drug Disco"},{"key":"433_CR47","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.bcp.2006.05.010","volume":"72","author":"SP Fricker","year":"2006","unstructured":"Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochemical Pharmacol. 2006;72:588\u201396.","journal-title":"Biochemical Pharmacol"},{"key":"433_CR48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0014-5793(02)03143-5","volume":"527","author":"S Hatse","year":"2002","unstructured":"Hatse S, Princen K, Bridger G, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002;527:255\u201362.","journal-title":"FEBS Lett"},{"key":"433_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.tox.2013.10.003","volume":"314","author":"M Gatti","year":"2013","unstructured":"Gatti M, Pattarozzi A, Bajetto A, Wurth R, Daga A, Fiaschi P, et al. Inhibition of CXCL12\/CXCR4 autocrine\/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology. 2013;314:209\u201320.","journal-title":"Toxicology"},{"key":"433_CR50","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4143\/crt.2010.42.4.225","volume":"42","author":"HY Kim","year":"2010","unstructured":"Kim HY, Hwang JY, Kim SW, Lee HJ, Yun HJ, Kim S, et al. The CXCR4 antagonist AMD3100 has dual effects on survival and proliferation of myeloma cells in vitro. Cancer Res Treat. 2010;42:225\u201334.","journal-title":"Cancer Res Treat"},{"key":"433_CR51","doi-asserted-by":"publisher","first-page":"8556","DOI":"10.1021\/jm100786g","volume":"53","author":"A Zhu","year":"2010","unstructured":"Zhu A, Zhan W, Liang Z, Yoon Y, Yang H, Grossniklaus HE, et al. Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J medicinal Chem. 2010;53:8556\u201368.","journal-title":"J medicinal Chem"},{"key":"433_CR52","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1126\/science.1261064","volume":"347","author":"L Qin","year":"2015","unstructured":"Qin L, Kufareva I, Holden LG, Wang C, Zheng Y, Zhao C, et al. Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science. 2015;347:1117\u201322.","journal-title":"Science"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00433-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00433-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00433-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:03:49Z","timestamp":1671062629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-022-00433-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1038\/s41417-022-00433-w","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,10]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJY holds shares in the company InLighta Biosciences LLC, which licenses the rights to commercialize ProCAs. JL holds shares in the company Codex Biosolution. JJY is a named inventor on issued or pending patents (US8173105 (EP1901659), US8367040 (EP3378496) contrast agents), (US9339559 (EP1928507, CA 2621763), US 10525150 targeted contrast agents), (US9956304 (EP2257316), US15\/910893, US17\/068215 contrast agents and imaging), (US15\/572,863 (WO16793465.2) targeted contrast agents). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}